PTGX
Protagonist Therapeutics (PTGX) Stock Valuation
Review Protagonist Therapeutics (PTGX) valuation with company data, supporting context and links to related investor research.
Research record updated: . Individual measures may refer to different reporting periods.
- Price to earnings
- 136.37
- Price to book
- 8.88
- BTI fair market cap
- $2.98B
- Premium or discount
- 197.96%
- Market cap
- $8.88B
Protagonist Therapeutics (PTGX) Stock Valuation research
The Protagonist Therapeutics valuation page presents the available multiples, profitability measures and BTI fair-value context for PTGX. Valuation should be compared with the company's growth, margins, balance sheet and relevant peers rather than judged by one multiple.
A premium may reflect stronger expected growth or quality, while a discount can reflect risk or weak expectations. Neither condition alone establishes that a stock is attractive or unattractive.
BTI fair value is a model estimate, not a quoted market price. The underlying assumptions and valuation date must be checked in the valuation tool before using the premium or discount. A missing multiple must not be interpreted as zero cost or zero risk.